Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn.

Michael MillerDeepak L BhattEliot A BrintonTerry A JacobsonPhilippe Gabriel StegArmando Lira PinedaSteven B KetchumRalph T DoyleJean-Claude TardifChristie M Ballantyne

Published in: European heart journal open (2023)

REDUCE-IT ClinicalTrials.gov number: NCT01492361.

Keyphrases

cardiovascular events
cardiovascular disease
metabolic syndrome
coronary artery disease
type diabetes
randomized controlled trial
systematic review
insulin resistance
glycemic control
ionic liquid
cardiovascular risk factors